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To the Editor:
Results of several recently pub-
lished randomized trials (RTs), suggest
that non-small cell lung cancer (NSCLC)
with different histologic patterns may
respond differently to various treatment
modalities and thus may represent dif-
ferent disease entities. In a phase III RT
comparing pemetrexed-cisplatin versus
gemcitabine-cisplatin for previously un-
treated advanced NSCLC, it was ob-
served that among patients with adenocar-
cinoma, overall survival was statistically
superior for pemetrexed compared with
gemcitabine (12.6 versus 10.9 months;
hazards ratio [HR]  0.84; 95% CI 
0.71–0.99; p  0.031) while the reverse
was seen with squamous histology (9.4
versus 10.8 months; HR  1.23; 95%
CI  1.00–1.51; p  0.05).1 Nonsqua-
mous histology (as a group) had results
similar to adenocarcinoma.1 Differences
in progression free survival based on
histology have also been observed in
other RTs using third-generation plati-
num-based doublets for chemo-naive
patients with advanced NSCLC.2,3 Even
in the second line setting, pemetrexed
has been demonstrated to result in supe-
rior median overall survival and pro-
gression free survival for patients with
adenocarcinoma.4 However, for squamous
or large-cell histology, the drug fared no
better than placebo.4 An individual pa-
tient data meta-analysis involving 2968
patients from 9 RTs compared the effi-
cacy of cisplatin versus carboplatin when
used in first line chemotherapy for ad-
vanced NSCLC.5 Here also, carboplatin
was associated with increased mortality
for nonsquamous histology (HR 1.12;
95% CI  1.01–1.23).5
In addition, there is evidence to
suggest that vascular endothelial growth
factor receptor antagonists and tyrosine
kinase inhibitors seem to exert benefi-
cial effects predominantly in patients
with adenocarcinoma and nonsquamous
histologic types. Bevacizumab has in
fact been shown to be detrimental in
squamous histology. Squamous histol-
ogy remains a favorable prognostic
factor for patients undergoing lung re-
sectional surgery in both prospective
and retrospective studies. The con-
verse has, however, been observed in
unresectable disease. Thus, besides
being an important predictive factor
for different therapeutic modalities,
histologic type remains an important
prognostic factor as well.
With the growing body of evi-
dence to suggest that NSCLC is a
heterogeneous disease, an important
question that arises is that are we still
justified in clubbing all the different
histologic types as one disease entity?
Identification of genomic, proteomic
and/or pharmacogenomic differences
between different histologic patterns
could be helpful in practicing ‘person-
alized medicine.’ However, carrying
out such kind of analyses for each
patient is usually not possible in health
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FIGURE 1. Overall survival in patients treated with erlotinib.
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care resource and economically con-
strained countries.
The next question is whether, in
the absence of any or all of these, can
NSCLC be reclassified or sub classi-
fied so that therapeutic decision mak-
ing does not get unnecessarily compli-
cated? One can debate whether it would
be more appropriate to classify lung
cancer into three main groups namely
small-cell, adenocarcinoma, and non-
adenocarcinoma (or alternatively, into
small-cell, squamous, and nonsqua-
mous). A second option could even be
to keep NSCLC as a broad group in-
tact but divide it further into adenocar-
cinoma, squamous, and nonadeno-
nonsquamous subtypes for the purpose
of management decision making.
It is not easy to resolve this issue and
conduct of RTs in the future on patients with
a particular histology is therefore required.
The ultimate aim of classification is that
each patient can be offered treatment that is
likely to produce the most clinical benefit
with the least possible toxicity profile even
if genomic, proteomic or pharmacog-
enomic analyses are not available.
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